SINO BIOPHARMACEUT HKD0.025 (SBMFF) Lifted to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of SINO BIOPHARMACEUT HKD0.025 (NASDAQ:SBMFF) from a hold rating to a buy rating in a research report sent to investors on Wednesday. They currently have $1.00 price target on the stock.
According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “
Shares of SINO BIOPHARMACEUT HKD0.025 (NASDAQ:SBMFF) opened at 0.99 on Wednesday. SINO BIOPHARMACEUT HKD0.025 has a 52-week low of $0.63 and a 52-week high of $0.99. The firm’s 50-day moving average is $0.89 and its 200 day moving average is $0.82. The stock has a market cap of $7.34 billion and a P/E ratio of 26.05.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for SINO BIOPHARMACEUT HKD0.025 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SINO BIOPHARMACEUT HKD0.025 and related stocks with our FREE daily email newsletter.